User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.

Primary tabs

download
  • Open access
  • PDF
  • 417.31 K
Wex, Jaro Sidhu, Manpreet Odeyemi, Isaac Abou-Setta, Ahmed M Retsa, Peny Tombal, Bertrand [UCL]

Eligard® formulations offer comparable efficacy and safety, but different dosing schedules require different number of visits. The 6 M formulation offers the greatest cost savings and should be considered the treatment of choice in eligible patients in Europe.

Document type Article de périodique (Journal article) – Article de recherche
Access type Accès libre
Publication date 2013
Language Anglais
Journal information "ClinicoEconomics and outcomes research : CEOR" - Vol. 5, p. 257-69 (2013)
Peer reviewed yes
issn 1178-6981
e-issn 1178-6981
Publication status Publié
Affiliations UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation
UCL - (SLuc) Service d'urologie
Keywords prostate ; cancer ; androgen ; leuprolide ; Eligard ; cost-effectiveness
Links
Bibliographic reference Wex, Jaro ; Sidhu, Manpreet ; Odeyemi, Isaac ; Abou-Setta, Ahmed M ; Retsa, Peny ; et. al. Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.. In: ClinicoEconomics and outcomes research : CEOR, Vol. 5, p. 257-69 (2013)
Permanent URL http://hdl.handle.net/2078.1/132670